Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study

Autologous stem cell transplantation (ASCT) is an established treatment approach for patients with multiple myeloma (MM) and lymphoma. This prospective pilot study aimed to evaluate the feasibility, efficacy, and safety of a reduced-dose cyclophosphamide plus etoposide (CE) regimen for peripheral blood stem cell (PBSC) mobilization. Fifteen patients (11 with MM and 4 with lymphoma) were enrolled in this single-center prospective study. The mobilization regimen consisted of etoposide (100 mg/m 2 on days 1–2) and cyclophosphamide (1000 mg/m 2 on day 1), followed by granulocyte colony-stimulating factor (G-CSF; 5–10 μg/kg/day) starting on day 7 until completion of collection. The mean total CD34 + cell yield was 7.53 × 10 6 /kg (range, 3.61–15.90). All patients achieved the minimum collection target of ≥ 2.0 × 10 6 CD34 + cells/kg, and 86.7% (13/15) achieved the optimal collection target of ≥ 5.0 × 10 6 CD34 + cells/kg. An optimal collection target was achieved after a single apheresis session in 73.3% (11/15) of patients. Grade 4 neutropenia occurred in one patient (6.7%), and no grade 3–4 thrombocytopenia was observed. In this pilot cohort, a reduced-dose CE regimen combined with G-CSF achieved adequate PBSC collection in all 15 patients without the use of plerixafor. These preliminary findings support the feasibility of this approach in selected patients and warrant further evaluation of its efficacy and safety in larger comparative studies.

Authors

Institutions

Publication Details

Journal
Annals of Hematology
Published
2026-11-21
DOI
https://doi.org/10.1007/s00277-026-07359-5
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study

许改香, Hongyan Tong, Liangshun You, Qiumei Yao et al.
Annals of Hematology
Hematopoietic Stem Cell Transplantation
article

Feasibility of reduced-dose cyclophosphamide plus etoposide for peripheral blood stem cell mobilization in patients with multiple myeloma and lymphoma: a prospective pilot study

许改香, Hongyan Tong, Liangshun You, Qiumei Yao, Xiang Zhang, Jiejing Qian, Haitao Meng, Xuewu Zhang, Xinping Zhou, Min Yang, Wenjuan Yu, Jie Jin
article en

Abstract

Autologous stem cell transplantation (ASCT) is an established treatment approach for patients with multiple myeloma (MM) and lymphoma. This prospective pilot study aimed to evaluate the feasibility, efficacy, and safety of a reduced-dose cyclophosphamide plus etoposide (CE) regimen for peripheral blood stem cell (PBSC) mobilization. Fifteen patients (11 with MM and 4 with lymphoma) were enrolled in this single-center prospective study. The mobilization regimen consisted of etoposide (100 mg/m 2 on days 1–2) and cyclophosphamide (1000 mg/m 2 on day 1), followed by granulocyte colony-stimulating factor (G-CSF; 5–10 μg/kg/day) starting on day 7 until completion of collection. The mean total CD34 + cell yield was 7.53 × 10 6 /kg (range, 3.61–15.90). All patients achieved the minimum collection target of ≥ 2.0 × 10 6 CD34 + cells/kg, and 86.7% (13/15) achieved the optimal collection target of ≥ 5.0 × 10 6 CD34 + cells/kg. An optimal collection target was achieved after a single apheresis session in 73.3% (11/15) of patients. Grade 4 neutropenia occurred in one patient (6.7%), and no grade 3–4 thrombocytopenia was observed. In this pilot cohort, a reduced-dose CE regimen combined with G-CSF achieved adequate PBSC collection in all 15 patients without the use of plerixafor. These preliminary findings support the feasibility of this approach in selected patients and warrant further evaluation of its efficacy and safety in larger comparative studies.

Annals of Hematology
First Affiliated Hospital Zhejiang University (CN), Zhejiang University (CN)
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon